Pro-Psyllium
Natural health product licensed in Canada
- Licence holder
- Propharmex Inc.
- NPN or DIN-HM
- 80085791
- Status
- Active licence
- Licence date
- 1 June 2018
- Revision date
- 23 April 2021
- Form
- Poudre
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Plantago ovata Source : Enveloppe | 5 Grammes | Not calculated |
Non-medicinal ingredients
Not provided.
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | minimum: 0.5 packet ; maximum: 1 packet | minimum: 1 day ; maximum: 4 days |
| Enfants | Not specified | 0.5 packet | minimum: 1 day ; maximum: 4 days |
Uses authorised in Canada
(Used in Herbal Medicine as a) bulk-forming laxative (Used in Herbal Medicine to) promote(s) bowel movements by increasing bulk volume and water content (Used in Herbal Medicine to) provide(s) gentle relief of constipation and/or irregularity.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. Do not use if you have diabetes mellitus in which blood sugar is difficult to regulate. Do not use if you have difficulty swallowing.
- Effets indésirables connus
Hypersensitivity, such as allergy, has been known to occur following inhaled and/or ingested psyllium; in which case, discontinue use May cause temporary gas and/or bloating.
- Précautions et mises en garde
Consult a health care practitioner if symptoms worsen or if laxative effect does not occur within seven days. Consult a health care practitioner immediately if you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product. Consult a health care practitioner prior to use if you are taking medications which inhibit peristaltic movement. Consult a health care practitioner prior to use if you have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, diseases of the oesophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel or appendicitis).
Source
Official Health Canada record, licence 80085791
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2021. Photograph the packaging to check whether it has changed. Photograph the packaging